COVID-19: Reasons for Guarded Optimism.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Works matching IS 11782595 AND DT 2021 AND VI 35 AND IP 2
Results: 8
1
2
Major Pharmaceutical Conferences and Courses: June to July 2021.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 139, doi. 10.1007/s40290-021-00384-x
- Publication type:
- Article
3
Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 81, doi. 10.1007/s40290-021-00383-y
- By:
- Publication type:
- Article
4
Klaus Rose. Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm: Academic Press, Cambridge, MA, USA. ISBN: 9780128238882 (print); 9780128242056 (online).
- Published in:
- 2021
- By:
- Publication type:
- Book Review
5
Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 123, doi. 10.1007/s40290-021-00380-1
- By:
- Publication type:
- Article
6
Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 93, doi. 10.1007/s40290-020-00377-2
- By:
- Publication type:
- Article
7
The conect4children (c4c) Consortium: Potential for Improving European Clinical Research into Medicines for Children.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 71, doi. 10.1007/s40290-020-00373-6
- By:
- Publication type:
- Article
8
The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions.
- Published in:
- Pharmaceutical Medicine, 2021, v. 35, n. 2, p. 113, doi. 10.1007/s40290-020-00372-7
- By:
- Publication type:
- Article